An (89)Zr-HDL PET tracer monitors response to a CSF1R inhibitor Journal Article
| Authors: | Mason, C. A.; Kossatz, S.; Carter, L. M.; Pirovano, G.; Brand, C.; Guru, N.; Pérez-Medina, C.; Lewis, J. S.; Mulder, W. J. M.; Reiner, T. |
| Article Title: | An (89)Zr-HDL PET tracer monitors response to a CSF1R inhibitor |
| Abstract: | The immune function within the tumor microenvironment has become a prominent therapeutic target, with tumor-associated macrophages (TAMs) playing a critical role in immune suppression. We propose an Zr-89-labeled high-density lipoprotein (Zr-89-HDL) nanotracer as a means of monitoring response to immunotherapy. Methods: Female MMTV-PyMT mice were treated with pexidartinib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, to reduce TAM density. The accumulation of Zr-89-HDL within the tumor was assessed using PET/CT imaging and autoradiography, whereas TAM burden was determined using immunofluorescence. Results: A significant reduction in Zr-89-HDL accumulation was observed in PET/CT images, with 2.9% +/- 0.3% and 3.7% +/- 0.2% injected dose/g for the pexidartinib- and vehicle-treated mice, respectively. This reduction was corroborated ex vivo and correlated with decreased TAM density. Conclusion: These results support the potential use of Zr-89-HDL nanoparticles as a PET tracer to quickly monitor the response to CSF1R inhibitors and other therapeutic strategies targeting TAMs. |
| Keywords: | inhibitor; immunotherapy; pet/ct imaging; breast-cancer; criteria; tumor-associated macrophages; hdl; csf1r |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 61 |
| Issue: | 3 |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2020-03-01 |
| Start Page: | 433 |
| End Page: | 436 |
| Language: | English |
| ACCESSION: | WOS:000518436700026 |
| DOI: | 10.2967/jnumed.119.230466 |
| PROVIDER: | wos |
| PMCID: | PMC7067531 |
| PUBMED: | 31420495 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work